Pulmonology

COPD

Advertisement

Conference Reporter® Podcast: Precision Medicine and Investigational Agents for Chronic Obstructive Pulmonary Disease

conference reporter by Frank C. Sciurba, MD, FCCP
Overview

Chronic obstructive pulmonary disease is increasingly being approached as a heterogeneous condition that can be differentiated by treatable traits, biomarkers, and distinct inflammatory pathways. Today’s podcast features a discussion with Frank C. Sciurba, MD, FCCP, on precision medicine and emerging biologic therapies, including findings highlighted at the CHEST 2026 Annual Meeting.

 

Following these presentations, featured expert Frank C. Sciurba, MD, FCCP, was interviewed by Conference Reporter Associate Editor-in-Chief Mona Shah, PharmD. Clinical perspectives from Dr Sciurba on these findings are presented here.

 

References

Cheng Y, Ding J, Li Z, Tong J, Yang C. The dawn of the dual-target era in respiratory disease: promise, pitfalls, and a roadmap for bispecific antibodies. Front Immunol. 2026;17:1906783. doi:10.3389/fimmu.2026.1906783

 

Fujino N, Sugiura H. Novel therapeutics for chronic obstructive pulmonary disease: from empirical bronchodilation to precision medicine. Respirology. 2026;31(6):561-577. doi:10.1002/resp.70244

 

Sciurba FC, Bhatt SP, Watz H, et al. Tozorakimab treatment improves daily respiratory symptoms in patients with chronic obstructive pulmonary disease: results from the OBERON and TITANIA studies [session: Top late-breaking abstracts: new drugs, new targets, new tools]. Abstract presented at: American College of Chest Physicians 2026 Annual Meeting; October 18-21, 2026; Phoenix, AZ.

 

Sciurba FC, Watz H, Bourdin A, et al; OBERON Trial Investigators; TITANIA Trial Investigators. Tozorakimab to prevent COPD exacerbations. N Engl J Med. 2026;395(17):1703-1716. doi:10.1056/NEJMoa2606998

 

Singh D, Brightling CE, Rabe KF, et al; COURSE Study Investigators. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respir Med. 2025;13(1):47-58. doi:10.1016/S2213-2600(24)00324-2

 

Washko G, Sciurba FC, Watz H, et al. Tozorakimab leads to long-term reductions in the number of lung segments with mucus plugs in patients with COPD: results from the phase 3 PROSPERO extension study [session: Top late-breaking abstracts: new trial data from bench to bronchoscope]. Abstract presented at: American College of Chest Physicians 2026 Annual Meeting; October 18-21, 2026; Phoenix, AZ.

 

Watz H, Sciurba FC, Bourdin A, et al. Long-term efficacy and safety of tozorakimab in patients with COPD: an integrated analysis of OBERON, TITANIA and the PROSPERO extension study [poster 3204] [session: Late-breaking scientific abstract posters (A): allergy and airway, obstructive lung diseases, pharmacotherapeutics]. Poster presented at: American College of Chest Physicians 2026 Annual Meeting; October 18-21, 2026; Phoenix, AZ.

 

Xie C, Wang K, Yang K, et al. Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits. Respir Res. 2025;26(1):274. doi:10.1186/s12931-025-03356-w

 

This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American College of Chest Physicians.

Frank C. Sciurba, MD, FCCP

Professor of Medicine and Education
Director, Emphysema COPD Research Center
Director, Pulmonary Function Exercise Physiology Laboratory
Director, Pulmonary Rehabilitation Program
University of Pittsburgh School of Medicine
Pittsburgh, PA

Advertisement